ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, on Wednesday announced financial results for the quarter ended March 31, 2026. In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5 percent compared with the same period in 2025, which RxSight said is largely reflective of lower light delivery device (LDD) unit volumes, consistent with expectations. Light adjustable lens (LAL) procedures decreased 0.4 percent year over year, the company advised.
